XML 41 R28.htm IDEA: XBRL DOCUMENT
v3.21.2

Revenue Recognition - Disaggregated Sales Analysis (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | $ 4,160 | $ 3,737 | $ 12,407 | $ 10,089
United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 3,019 | 2,748 | 8,903 | 7,357
International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,141 | 989 | 3,504 | 2,732
Orthopaedics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,529 | 1,317 | 4,641 | 3,433
Orthopaedics | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,064 | 937 | 3,222 | 2,412
Orthopaedics | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 465 | 380 | 1,419 | 1,021
Orthopaedics | Knees |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 439 | 435 | 1,325 | 1,108
Orthopaedics | Knees | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 321 | 332 | 964 | 833
Orthopaedics | Knees | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 118 | 103 | 361 | 275
Orthopaedics | Hips |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 328 | 334 | 990 | 866
Orthopaedics | Hips | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 199 | 223 | 606 | 564
Orthopaedics | Hips | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 129 | 111 | 384 | 302
Orthopaedics | Trauma and Extremities |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 639 | 430 | 1,953 | 1,152
Orthopaedics | Trauma and Extremities | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 447 | 285 | 1,362 | 753
Orthopaedics | Trauma and Extremities | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 192 | 145 | 591 | 399
Orthopaedics | Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 123 | 118 | 373 | 307
Orthopaedics | Other | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 97 | 97 | 290 | 262
Orthopaedics | Other | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 26 | 21 | 83 | 45
MedSurg |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,755 | 1,600 | 5,124 | 4,546
MedSurg | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1,397 | 1,269 | 4,007 | 3,567
MedSurg | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 358 | 331 | 1,117 | 979
MedSurg | Instruments |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 525 | 467 | 1,511 | 1,308
MedSurg | Instruments | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 415 | 369 | 1,171 | 1,028
MedSurg | Instruments | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 110 | 98 | 340 | 280
MedSurg | Endoscopy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 525 | 467 | 1,512 | 1,238
MedSurg | Endoscopy | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 418 | 380 | 1,179 | 997
MedSurg | Endoscopy | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 107 | 87 | 333 | 241
MedSurg | Medical |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 636 | 600 | 1,898 | 1,819
MedSurg | Medical | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 496 | 455 | 1,457 | 1,363
MedSurg | Medical | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 140 | 145 | 441 | 456
MedSurg | Sustainability |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 69 | 66 | 203 | 181
MedSurg | Sustainability | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 68 | 65 | 200 | 179
MedSurg | Sustainability | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 1 | 1 | 3 | 2
Neurotechnology and Spine |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 876 | 820 | 2,642 | 2,110
Neurotechnology and Spine | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 558 | 542 | 1,674 | 1,378
Neurotechnology and Spine | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 318 | 278 | 968 | 732
Neurotechnology and Spine | Neurotechnology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 594 | 518 | 1,775 | 1,370
Neurotechnology and Spine | Neurotechnology | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 357 | 323 | 1,063 | 835
Neurotechnology and Spine | Neurotechnology | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 237 | 195 | 712 | 535
Neurotechnology and Spine | Spine |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 282 | 302 | 867 | 740
Neurotechnology and Spine | Spine | United States |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | 201 | 219 | 611 | 543
Neurotechnology and Spine | Spine | International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Net sales | $ 81 | $ 83 | $ 256 | $ 197

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_KneesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_HipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_TraumaandExtremitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_OtherOrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_MedsurgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_InstrumentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_EndoscopyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_MedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_SustainabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=syk_NeurotechnologyAndSpineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_NeurotechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=syk_SpineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |